1. Home
  2. EVG vs ELTX Comparison

EVG vs ELTX Comparison

Compare EVG & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EVG
  • ELTX
  • Stock Information
  • Founded
  • EVG 2005
  • ELTX 2011
  • Country
  • EVG United States
  • ELTX United States
  • Employees
  • EVG N/A
  • ELTX N/A
  • Industry
  • EVG Investment Managers
  • ELTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • EVG Finance
  • ELTX Health Care
  • Exchange
  • EVG Nasdaq
  • ELTX Nasdaq
  • Market Cap
  • EVG 148.1M
  • ELTX 121.7M
  • IPO Year
  • EVG N/A
  • ELTX N/A
  • Fundamental
  • Price
  • EVG $11.00
  • ELTX $9.89
  • Analyst Decision
  • EVG
  • ELTX Strong Buy
  • Analyst Count
  • EVG 0
  • ELTX 2
  • Target Price
  • EVG N/A
  • ELTX $11.00
  • AVG Volume (30 Days)
  • EVG 49.4K
  • ELTX 36.7K
  • Earning Date
  • EVG 01-01-0001
  • ELTX 08-12-2025
  • Dividend Yield
  • EVG 8.68%
  • ELTX N/A
  • EPS Growth
  • EVG N/A
  • ELTX N/A
  • EPS
  • EVG N/A
  • ELTX N/A
  • Revenue
  • EVG N/A
  • ELTX N/A
  • Revenue This Year
  • EVG N/A
  • ELTX N/A
  • Revenue Next Year
  • EVG N/A
  • ELTX N/A
  • P/E Ratio
  • EVG N/A
  • ELTX N/A
  • Revenue Growth
  • EVG N/A
  • ELTX N/A
  • 52 Week Low
  • EVG $9.13
  • ELTX $3.70
  • 52 Week High
  • EVG $10.86
  • ELTX $10.39
  • Technical
  • Relative Strength Index (RSI)
  • EVG 48.64
  • ELTX 75.55
  • Support Level
  • EVG $10.98
  • ELTX $9.14
  • Resistance Level
  • EVG $11.15
  • ELTX $10.39
  • Average True Range (ATR)
  • EVG 0.12
  • ELTX 0.57
  • MACD
  • EVG -0.02
  • ELTX 0.08
  • Stochastic Oscillator
  • EVG 14.89
  • ELTX 79.34

About EVG Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest

Eaton Vance Short Duration Diversified Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income with a secondary objective of seeking capital appreciation to the extent consistent with its primary goal. The portfolio of investments consists of business equipment and services, automotive, cable and satellite television, chemicals and plastics, food products, and other areas.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.

Share on Social Networks: